---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-211462"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2025-09-22T23:59:59+00:00"
generated_at: "2026-05-17T05:59:31.998821+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Benitec Biopharma FY2025 net loss $37.9M ($1.05/sh); BB-301 DSMB clears Cohort 2 enrollment

## Summary
- Net loss $37.9M ($1.05/share) vs $22.4M ($1.22/share) in FY2024; total expenses $41.8M (up 86%).
- R&D expense $18.3M (up 17%) on BB-301 clinical development; G&A $23.4M (up 235%) driven by stock-based comp $14.5M.
- Cash and equivalents $97.7M (up from $50.9M) after equity offerings.
- DSMB recommended continuation; Cohort 2 enrollment and interim Cohort 1 data both expected Q4 2025.
- BB-301 Phase 1b/2a for OPMD with dysphagia; no revenue reported.

## SEC filing metadata
- accession: 0001193125-25-211462
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2025-09-22T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312525211462/0001193125-25-211462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312525211462/bntc-20250922.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-211462
- JSON: https://secwatch.observer/filing/0001193125-25-211462.json
- Plain text: https://secwatch.observer/filing/0001193125-25-211462.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.